✅ Key Product Benefits

• Dual mode of action: Empagliflozin (SGLT2 inhibitor) increases urinary glucose excretion. Metformin suppresses hepatic glucose output and enhances insulin sensitivity—combined they lower blood glucose more effectively. turn0search0turn0search3

• Simplified dosing: Combines two medications in one tablet—taken twice daily with meals—which enhances adherence compared to separate meds. turn0search1turn0search0

• Cardiometabolic advantage: Empagliflozin adds cardiovascular and weight benefits (e.g., modest weight loss, blood pressure reduction) beyond blood sugar control. turn0search12turn0search9

ℹ️ Dosage & Administration

• Standard regimen: 5 mg Empagliflozin + 500 mg Metformin taken twice daily with meals

• Dose adjustment: Gradual titration of Metformin helps minimize gastrointestinal side effects.

• Renal function caution: Contraindicated if eGFR < 45 mL/min; adjust based on renal status and hydration. turn0search1turn0search0turn0search6

⚠️ Safety & Side Effects

• Common adverse effects:

  • Empagliflozin: Increased urination, UTI, genital yeast infections

  • Metformin: Nausea, diarrhea, abdominal discomfort

• Serious warnings:

  • Risk of lactic acidosis in settings of renal impairment, dehydration, or acute illness

  • Volume depletion: Monitor blood pressure and fluid status, especially in elderly or diuretic users

  • Hypoglycemia risk if combined with sulfonylureas or insulin

• Contraindications: Known hypersensitivity, acute metabolic acidosis, severe renal impairment (eGFR <30 mL/min), severe hepatic disease, dehydration. Not recommended during pregnancy or breastfeeding. turn0search1turn0search0

🧾 Quick Reference Table

✅ Bottom Line

Adempa‑M 5 mg + 500 mg Tablet is a practical, clinically effective option for type 2 diabetes management. It merges the benefits of SGLT2 inhibition and Metformin in a simplified dosage form—a choice well-suited for patients needing better glycemic control plus metabolic advantages.